"rationale","id","versionIdentifier","instanceType","uuid:ID"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2","StudyVersion","118cf990-f74a-4c21-b8ef-07b3e90a0585"
